Sun Pharmaceutical Industries Ltd (SUN.NS)
971.00INR
1:46pm IST
Rs-0.90 (-0.09%)
Rs971.90
Rs965.00
Rs977.00
Rs962.10
400,359
1,089,705
Rs1,084.80
Rs580.00
SUN.NS
About
Overall
| Beta: | 0.55 |
| Market Cap (Mil.): | Rs1,006,482.00 |
| Shares Outstanding (Mil.): | 1,035.58 |
| Dividend: | 5.00 |
| Yield (%): | 0.44 |
Financials
| SUN.NS | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | 33.39 | 31.05 | 31.28 |
| EPS (TTM): | 29.11 | -- | -- |
| ROI: | 24.24 | 19.56 | 18.90 |
| ROE: | 22.08 | 20.32 | 19.80 |
Sun Pharma slumps after $550 mln patent suit settlement with Pfizer
MUMBAI - Shares in Sun Pharmaceutical Industries more than 5 percent after the company settled a patent suit with Pfizer Inc related to its acid-reflux drug for $550 million.
India's Sun Pharma slumps after $550 mln patent suit settlement with Pfizer
MUMBAI, June 13 - Shares in India's Sun Pharmaceutical Industries Ltd fell 4.8 percent in pre-open trading after the company settled a patent suit with Pfizer Inc related to its acid-reflux drug for $550 million.
Sweden's Meda sale talks founder on valuation: source
STOCKHOLM/MUMBAI - Swedish drugmaker Meda said it was not discussing being taken over, after a source with knowledge of the matter said talks about a deal with India's Sun Pharmaceutical Industries had foundered on valuation.
UPDATE 3-Sweden's Meda sale talks founder on valuation - source
* Generic drugs sector busy with deals (Adds Meda announcement on Cipla)
Swedish drugmaker Meda says not in sale talks
STOCKHOLM - Swedish drugmaker Meda said on Wednesday it was not in talks on a takeover, a week after sources said India's Sun Pharmaceutical Industries was looking to buy the company and had approached banks for financing.
MARKET EYE-India's Sun Pharma gains; Meda says no takeover talks
* Shares in India's Sun Pharmaceutical Industries Ltd rise 2 percent after Swedish drugmaker Meda AB said it was not involved in discussions with a potential buyer, contradicting reports that the two companies were in talks. * Two sources with direct knowledge of the situation had told Reuters on May 31 that Sun Pharmaceutical was in talks to buy Meda for $5 billion to $6 billion. * After those reports, investors had worried Sun would have to assume significant debt to finance the purchase.
Swedish drug firm Meda says not in discussions over possible sale
STOCKHOLM, June 5 - Swedish drugmaker Meda AB said on Wednesday that it was not involved in discussions with a potential buyer a week after sources said that India's Sun Pharmaceutical Industries was in talks to buy a controlling stake in the firm.
Indian shares slip to almost 1-month closing low; outlook grim
* BSE index falls 0.76 pct; NSE ends 0.78 pct lower * Auto stocks slump on weak sales in May * Infosys shares jump on founder Murthy's return as chairman By Abhishek Vishnoi MUMBAI, June 3 - Indian shares fell for a second straight session on Monday to their lowest close in nearly a month as Sun Pharmaceutical Industries Ltd dropped on reports of its talks to buy Sweden's Meda AB, while Maruti Suzuki India Ltd slumped after sales declined 14.4 percent in May. Shar
MARKET EYE-Indian shares fall; Maruti, Sun Pharma hit
* India's main BSE index falls 0.62 percent and the broader NSE index is down 0.66 percent. * Shares in Maruti Suzuki India Ltd fall 2.4 percent after the automaker's sales declined 14.4 percent in May, compared with a year earlier. * Sun Pharmaceutical Industries Ltd falls 2.3 percent on media reports the company is in talks to buy Sweden's Meda AB for between $5 billion and $6 billion to boost its generics business in developed markets. * However, Infosys Ltd gain 4.6 percent on bets the r
Indian shares snap 3-day winning streak; lenders fall, Sun Pharma surges
MUMBAI, May 29 - Indian shares fell on Wednesday, snapping a three-day winning streak, as lenders such as ICICI Bank fell on caution ahead of quarterly economic growth data and the expiry of May derivative contracts later this week.
Earnings vs. 
Estimates
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
